Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -57M | -35M | -52M | -90M | -79M |
| EBITDA | -36M | -27M | -51M | -90M | -79M |
| Net Income | -57M | -31M | -52M | -90M | -77M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.945
+4.65% today
1Y Change
-92.84%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Quince Therapeutics, Inc. (QNCX) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $0.94 and down 92.8% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -28.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -28.2%, free cash flow -29.9% with operating margin 0.0% and ROIC -73.8%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines QNCX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
QNCX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
QNCX Max Drawdown
-98.18%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for QNCX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$76.8M
+14.6% YoY
Free Cash Flow
-$50.9M
+19.4% YoY
Revenue Growth
+0.0%
EPS Growth
-28.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -57M | -35M | -52M | -90M | -79M |
| EBITDA | -36M | -27M | -51M | -90M | -79M |
| Net Income | -57M | -31M | -52M | -90M | -77M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6M | 21M | 45M | 70M | 67M |
| Total Assets | 114M | 180M | 104M | 133M | 189M |
| Total Liabilities | 84M | 95M | 3M | 15M | 17M |
| Shareholder Equity | 30M | 85M | 101M | 119M | 172M |
| Total Debt | 15M | 14M | 453K | 1M | 446K |
| Net Debt | 9M | -7M | -44M | -69M | -66M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
51M
+19.2% YoY
Capital Expenditures
52K
+71.1% YoY
Free Cash Flow
51M
+19.4% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
7743.6%
Debt / Equity
-0.51x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.